Sirtex studies are totally irrelevant to outlook for OSL technology, although Sirtex claimed a positive result within the liver for their SIRFLOX.
OSL has a completely different technology and is claiming a disease control rate of 82% from 4 small studies of 17 patients, which IMHO is pretty significant.
OSL is capitalised at $32M of which $8.85M is cash and credits, and exhibits a burn rate of $1.38M per quarter.
Sirtex is a $2 billion company so upside for OSL is massive.
Application for CE mark for both liver and pancreatic markets is very significant development.
1.5 day turnover of almost 55M shares is largest in OSL history AND to-day's sell down is a magnificent buy opportunity just bought more on the dip at $0.088. Day traders must be suffering from severe doses of bi polar disorder. Good luck to all longs.
OSL Price at posting:
8.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)